Potentials of contemporary biomarkers in assessing skin lesions and fibrous activity in systemic scleroderma
Journal Title: Український журнал дерматології, венерології, косметології - Year 2019, Vol 0, Issue 3
Abstract
Systemic scleroderma (SSD) is a systemic disease with heterogeneous clinical manifestations of skin and internal organs lesions. It is believed that the trigger for its development is the initial damage of the blood vessels leading to an inflammatory reaction and accumulation of collagen and other extracellular matrix components. One of the important aspects of managing these patients is the identification of patients with a high risk of internal organ and skin damage and control of fibrotic activity in response to therapy. Diagnosis and control of skin lesions in SSD is performed by clinical observation and the use of methods such as skin count on the Rodnan scale (mRSS), durometry, goniometry, and ultrasonic skin thickness determination. However, the sensitivity of these methods is quite low, they are not validated for use at present and are rather laborious and subjective. In addition, these methods do not provide information about the fibrotic activity. These disadvantages of the above mentioned methods can be compensated by studying the biomarkers of skin lesions in SSD which reflect not only the inflammatory and fibrotic activity, but also can be used for evaluating the prognosis and effectiveness of the treatment. This review focuses on biomarkers of skin lesions in patients with scleroderma. These include the growth factors, cytokines and proteases, their inhibitors, as well as some proteins of the extracellular matrix, especially collagens, which were identified in skin biopsies and in serum samples of patients with SSD. The review summarizes noninvasive physical and laboratory studies that provide a better understanding of the fibrotic activity of the disease, can be effectively used to evaluate a potential therapeutic response and find best treatment options for patients with SSD.
Authors and Affiliations
I. Yu. Golovach, Ye. D. Yehudina
Keywords
Related Articles
- EP ID EP672781
- DOI 10.30978/UJDVK2019-3-113
- Views 92
- Downloads 0
Original or generic combined topic glucocorticosteroid. What are the differences?
The task of the doctor is to choose the optimal (from a clinical and economic point of view) for the patient drug among numerous analogues drugs containing the same active pharmaceutical ingredient (API). In the pharmaco...
The use of plasma enriched with platelets and fractional CO2 laser for the treatment of post-acne
Objective — to develop a comprehensive method for restoring facial skin with postacne symptoms. Materials and methods. From 2015 till 2016 there were 30 patients with postacne symptoms under our supervision. Of these,...
Potentials of contemporary biomarkers in assessing skin lesions and fibrous activity in systemic scleroderma
Systemic scleroderma (SSD) is a systemic disease with heterogeneous clinical manifestations of skin and internal organs lesions. It is believed that the trigger for its development is the initial damage of the blood vess...
Peptides in cosmeceuticals
Skin aging is part of human global aging which becomes evident along the years following different ways in organs, tissues and cells. Aging of the internal organs is masked whilst the skin is the first organ displaying v...
Results of clinical research on therapy with Acnevac® in patients with acne vulgaris
The article presents the results of clinical research on effectiveness of Acnevac® cps in the therapy of grade I — grade IV acne vulgaris. The research was conducted at four dermatological clinics in the Czech Republic f...